• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

B细胞中的免疫检查点:开启癌症治疗的新潜力

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment.

作者信息

Shi Xiaoye, Cheng Xiangshu, Jiang Aimin, Shi Wenjie, Zhu Lingxuan, Mou Weiming, Glaviano Antonino, Liu Zaoqu, Cheng Quan, Lin Anqi, Wang Linhui, Luo Peng

机构信息

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China.

The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China.

出版信息

Adv Sci (Weinh). 2024 Dec;11(47):e2403423. doi: 10.1002/advs.202403423. Epub 2024 Nov 7.

DOI:10.1002/advs.202403423
PMID:39509319
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11653663/
Abstract

B cells are crucial component of humoral immunity, and their role in the tumor immune microenvironment (TME) has garnered significant attention in recent years. These cells hold great potential and application prospects in the field of tumor immunotherapy. Research has demonstrated that the TME can remodel various B cell functions, including proliferation, differentiation, antigen presentation, and antibody production, thereby invalidating the anti-tumor effects of B cells. Concurrently, numerous immune checkpoints (ICs) on the surface of B cells are upregulated. Aberrant B-cell IC signals not only impair the function of B cells themselves, but also modulate the tumor-killing effects of other immune cells, ultimately fostering an immunosuppressive TME and facilitating tumor immune escape. Blocking ICs on B cells is beneficial for reversing the immunosuppressive TME and restoring anti-tumor immune responses. In this paper, the intricate connection between B-cell ICs and the TME is delved into, emphasizing the critical role of targeting B-cell ICs in anti-tumor immunity, which may provide valuable insights for the future development of tumor immunotherapy based on B cells.

摘要

B细胞是体液免疫的关键组成部分,近年来它们在肿瘤免疫微环境(TME)中的作用备受关注。这些细胞在肿瘤免疫治疗领域具有巨大的潜力和应用前景。研究表明,TME可重塑多种B细胞功能,包括增殖、分化、抗原呈递和抗体产生,从而使B细胞的抗肿瘤作用失效。同时,B细胞表面的众多免疫检查点(IC)上调。异常的B细胞IC信号不仅损害B细胞自身的功能,还会调节其他免疫细胞的杀伤肿瘤作用,最终促进免疫抑制性TME的形成并促进肿瘤免疫逃逸。阻断B细胞上的IC有利于逆转免疫抑制性TME并恢复抗肿瘤免疫反应。本文深入探讨了B细胞IC与TME之间的复杂联系,强调了靶向B细胞IC在抗肿瘤免疫中的关键作用,这可能为基于B细胞的肿瘤免疫治疗的未来发展提供有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/510ac8c10a45/ADVS-11-2403423-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/c9ac7773636c/ADVS-11-2403423-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/a60400c92b2c/ADVS-11-2403423-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/93dcd39815c6/ADVS-11-2403423-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/2d32f5fe9c2a/ADVS-11-2403423-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/510ac8c10a45/ADVS-11-2403423-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/c9ac7773636c/ADVS-11-2403423-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/a60400c92b2c/ADVS-11-2403423-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/93dcd39815c6/ADVS-11-2403423-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/2d32f5fe9c2a/ADVS-11-2403423-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11653663/510ac8c10a45/ADVS-11-2403423-g007.jpg

相似文献

1
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment.B细胞中的免疫检查点:开启癌症治疗的新潜力
Adv Sci (Weinh). 2024 Dec;11(47):e2403423. doi: 10.1002/advs.202403423. Epub 2024 Nov 7.
2
Targeting immune checkpoints on myeloid cells: current status and future directions.靶向髓系细胞上的免疫检查点:现状与未来方向。
Cancer Immunol Immunother. 2025 Jan 3;74(2):40. doi: 10.1007/s00262-024-03856-6.
3
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.肿瘤微环境对免疫检查点阻断治疗的反应。
Front Immunol. 2020 May 7;11:784. doi: 10.3389/fimmu.2020.00784. eCollection 2020.
4
Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.癌症干细胞靶向免疫治疗的挑战和机遇包括免疫检查点抑制剂、癌症干细胞-树突状细胞疫苗、嵌合抗原受体免疫细胞和修饰的外泌体。
J Biochem Mol Toxicol. 2024 Jun;38(6):e23719. doi: 10.1002/jbt.23719.
5
Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface.癌症免疫治疗中免疫检查点调节的新兴可用药靶:冰山在水面之下。
Apoptosis. 2024 Dec;29(11-12):1879-1913. doi: 10.1007/s10495-024-02022-8. Epub 2024 Oct 1.
6
Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors.针对在多种实体瘤中对现有检查点疗法无反应的癌症患者,将 LLT1 作为一种潜在的免疫疗法选择。
BMC Cancer. 2024 Nov 7;24(1):1365. doi: 10.1186/s12885-024-13074-z.
7
Immune checkpoints in the tumor microenvironment.肿瘤微环境中的免疫检查点。
Semin Cancer Biol. 2020 Oct;65:1-12. doi: 10.1016/j.semcancer.2019.06.021. Epub 2019 Jun 29.
8
Turning Cold into Hot: Firing up the Tumor Microenvironment.化寒为热:点燃肿瘤微环境
Trends Cancer. 2020 Jul;6(7):605-618. doi: 10.1016/j.trecan.2020.02.022. Epub 2020 Mar 21.
9
LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer.在非小细胞肺癌中,LKB1通过Skp2介导的PD-L1蛋白泛素化决定对免疫疗法的敏感性。
J Immunother Cancer. 2024 Dec 18;12(12):e009444. doi: 10.1136/jitc-2024-009444.
10
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.纳米胶束保护紫杉醇的免疫激活作用,并使肿瘤对抗 PD-1 免疫治疗敏感。
Theranostics. 2020 Jul 9;10(18):8382-8399. doi: 10.7150/thno.45391. eCollection 2020.

引用本文的文献

1
ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in Estrogen Receptor-Positive/HER2-Negative Breast Cancer.ESR1表达与雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌中的免疫细胞浸润及免疫检查点抑制剂反应呈负相关。
Ann Surg Oncol. 2025 Sep 16. doi: 10.1245/s10434-025-18260-2.
2
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.同源重组缺陷型癌症中独特的肿瘤免疫微环境格局。
Biomark Res. 2025 Aug 20;13(1):108. doi: 10.1186/s40364-025-00814-x.
3
Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.

本文引用的文献

1
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.B 细胞浸润与头颈部鳞状细胞癌接受程序性死亡蛋白 1 抑制剂治疗后的生存结局相关。
Ann Oncol. 2024 Apr;35(4):340-350. doi: 10.1016/j.annonc.2023.12.011. Epub 2023 Dec 28.
2
Fcγ receptors and immunomodulatory antibodies in cancer.Fcγ 受体与癌症的免疫调节抗体
Nat Rev Cancer. 2024 Jan;24(1):51-71. doi: 10.1038/s41568-023-00637-8. Epub 2023 Dec 7.
3
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy.
蛋白质空间结构与人工智能相遇:革新精准医学中的药物协同 - 拮抗作用
Adv Sci (Weinh). 2025 Sep;12(33):e07764. doi: 10.1002/advs.202507764. Epub 2025 Aug 7.
4
p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma.p53与程序性死亡配体1(PD-L1)共表达预示弥漫性大B细胞淋巴瘤预后不良。
Discov Oncol. 2025 Jul 6;16(1):1270. doi: 10.1007/s12672-025-03062-5.
5
Lactylation-Related Gene LILRB4 Predicts the Prognosis and Immunotherapy of Prostate Cancer Based on Machine Learning.基于机器学习的乳酸化相关基因LILRB4预测前列腺癌的预后及免疫治疗效果
J Cell Mol Med. 2025 Jun;29(12):e70669. doi: 10.1111/jcmm.70669.
6
TMEM115: a promising marker for glioma immunotherapy and prognosis.跨膜蛋白115:一种有前景的神经胶质瘤免疫治疗和预后标志物。
Front Immunol. 2025 Jun 9;16:1598499. doi: 10.3389/fimmu.2025.1598499. eCollection 2025.
7
Distribution characteristics and prognostic value of TIM-1 in patients with lung adenocarcinoma.TIM-1在肺腺癌患者中的分布特征及预后价值
Front Immunol. 2025 May 30;16:1602868. doi: 10.3389/fimmu.2025.1602868. eCollection 2025.
8
TSPAN4 fibroblasts coordinate metastatic niche assembly through migrasome-driven metabolic reprogramming and stromal-immune crosstalk in pancreatic adenocarcinoma.TSPAN4 成纤维细胞通过迁移体驱动的代谢重编程和胰腺腺癌中的基质 - 免疫串扰来协调转移微环境的组装。
Front Immunol. 2025 May 15;16:1594879. doi: 10.3389/fimmu.2025.1594879. eCollection 2025.
9
Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor.利用肿瘤引流淋巴结的力量:揭示免疫检查点抑制剂的预测性生物标志物。
Explor Target Antitumor Ther. 2025 May 13;6:1002315. doi: 10.37349/etat.2025.1002315. eCollection 2025.
10
Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.非小细胞肺癌中的肿瘤浸润性B细胞:当前见解与未来方向
Cancer Cell Int. 2025 Feb 26;25(1):68. doi: 10.1186/s12935-025-03668-3.
B细胞免疫检查点TIM-1:肿瘤免疫治疗的潜在靶点。
Signal Transduct Target Ther. 2023 Oct 20;8(1):389. doi: 10.1038/s41392-023-01643-w.
4
Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment.癌症治疗中 PD-1/PD-L1 检查点抑制剂的现状与未来方向。
Biomolecules. 2023 Aug 1;13(8):1209. doi: 10.3390/biom13081209.
5
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.联合免疫检查点阻断对肾细胞癌的优先 B 细胞分化与临床反应和自身免疫反应相关。
Cancer Immunol Immunother. 2023 Nov;72(11):3543-3558. doi: 10.1007/s00262-023-03505-4. Epub 2023 Aug 7.
6
Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta.癌相关成纤维细胞通过 TGF-β 驱动活化 T 细胞中 CXCL13 的产生。
Front Immunol. 2023 Jul 13;14:1221532. doi: 10.3389/fimmu.2023.1221532. eCollection 2023.
7
TIM-1ly roles for B cells.B细胞的TIM-1样作用。
Nat Immunol. 2023 Aug;24(8):1211. doi: 10.1038/s41590-023-01582-2.
8
Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response.Siglec-9 在胶质母细胞瘤的巨噬细胞上作为免疫检查点分子发挥作用,限制 T 细胞的启动和免疫治疗反应。
Nat Cancer. 2023 Sep;4(9):1273-1291. doi: 10.1038/s43018-023-00598-9. Epub 2023 Jul 17.
9
Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers.肿瘤浸润 B 细胞在人类癌症中的生发中心依赖性和非依赖性免疫应答。
Cell Mol Immunol. 2023 Sep;20(9):1040-1050. doi: 10.1038/s41423-023-01060-7. Epub 2023 Jul 7.
10
B-cell-specific checkpoint molecules that regulate anti-tumour immunity.B 细胞特异性检查点分子调节抗肿瘤免疫。
Nature. 2023 Jul;619(7969):348-356. doi: 10.1038/s41586-023-06231-0. Epub 2023 Jun 21.